文献速递贫血与红细胞疾病

Mask 小鼠组织铁分布及口服铁剂效果

Iron distribution in different tissues of homozygous Mask (msk/msk) mice and the effects of oral iron treatments.
PubMed 文献 · Am J Hematol · 2021-08-14

研究在 IRIDA 小鼠模型 Mask 中比较不同年龄和性别纯合子与杂合子的组织铁状态,并评估口服铁剂效果。在 msk/msk 小鼠中,硫酸亚铁未升高血红蛋白,而蔗糖铁从 11.50 ± 0.60 升至 13.53 ± 0.64 g/dl,提示可能通过替代途径吸收。

要点

  • msk/msk 小鼠模拟 IRIDA,口服硫酸亚铁未能升高血红蛋白。
  • 蔗糖铁在 msk/msk 小鼠中升高血红蛋白,首周明显。
  • 蔗糖铁可能为 IRIDA 患者口服补铁的有前景选择。

核心结论

  • 蔗糖铁可能为 IRIDA 患者口服补铁的有前景选择。

研究设计与样本

  • 使用 IRIDA 小鼠模型 Mask,比较纯合子 msk/msk 与无症状杂合子 msk/wt 在不同年龄和性别下的多器官铁状态主要参数。
  • 分析羰基铁饮食作为对照补铁的效果,并主要比较硫酸亚铁与蔗糖铁两种口服铁剂。

主要发现

  • 在贫血对照小鼠中,两种口服铁剂在 2-4 周内将血红蛋白从 11.40 ± 0.60 纠正至 15.38 ± 1.71 g/dl。
  • 在 msk/msk 小鼠中,硫酸亚铁未升高血红蛋白,可能因膜铁转运蛋白/铁调素依赖性吸收。
  • 在 msk/msk 小鼠中,蔗糖铁将血红蛋白从 11.50 ± 0.60 升至 13.53 ± 0.64 g/dl,主要在第一周,4 周时稳定在 13.30 ± 0.80 g/dl,可能因替代吸收途径。

临床怎么用

  • 对于 IRIDA 患者,口服硫酸亚铁可能无效,可考虑蔗糖铁作为口服补铁选项。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Iron-refractory iron deficiency anemia (IRIDA) is an autosomal recessive disorder caused by genetic mutations on TMPRSS6 gene which encodes Matriptase2 (MT2). An altered MT2 cannot appropriately suppress hepatic BMP6/SMAD signaling in case of low iron, hence hepcidin excess blocks dietary iron absorption, leading to a form of anemia resistant to oral iron supplementation. In this study, using the IRIDA mouse model Mask, we characterized homozygous (msk/msk) compared to asymptomatic heterozygous (msk/wt) mice, assessing the major parameters of iron status in different organs, at different ages in both sexes. The effect of carbonyl iron diet was analyzed as control iron supplementation being used for many studies in mice. It resulted effective in both anemic control and msk/msk mice, as expected, even if there is no information about its mechanism of absorption. Then, we mainly compared two forms of oral iron supplement, largely used for humans: ferrous sulfate and Sucrosomial iron. In anemic control mice, the two oral formulations corrected hemoglobin levels from 11.40 ± 0.60 to 15.38 ± 1.71 g/dl in 2-4 weeks. Interestingly, in msk/msk mice, ferrous sulfate did not increase hemoglobin likely due to ferroportin/hepcidin-dependent absorption, whereas Sucrosomial iron increased it from 11.50 ± 0.60 to 13.53 ± 0.64 g/dl mainly in the first week followed by a minor increase at 4 weeks with a stable level of 13.30 ± 0.80 g/dl, probably because of alternative absorption. Thus, Sucrosomial iron, already used in other conditions of iron deficiency, may represent a promising option for oral iron supplementation in IRIDA patients.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Asperti M, Brilli E, Denardo A, et al. Iron distribution in different tissues of homozygous Mask (msk/msk) mice and the effects of oral iron treatments. Am J Hematol. 2021. PMID: 34343368. doi:10.1002/ajh.26311

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。